Identification of Beta-Lactamase-Producing Pseudomonas aeruginosa with Multiple Antibiotic Resistances

Document Type : Original Article (s)

Authors

1 Assistant Professor, Department of Microbiology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

2 Associate Professor, Department of Microbiology, School of Medicine Isfahan University of Medical Sciences, Isfahan, Iran

3 Assistant Professor, Department of Biostatitics and Epidemiology, School of Public Health, Tehran University of Medical Sciences, Isfahan, Iran

4 Department of Microbiology, School of Medicine Isfahan University of Medical Sciences, Isfahan, Iran

5 PhD Student, Department of Medical Microbiology, School of Medicine And Student Research Committee, Isfahan University of Medical Sciences, Isfahan, Iran

Abstract

Background: The clinical use of antibiotics in treatment of Pseudomonas aeruginosa infections causes resistant to multiple drugs increasingly. P. aeruginosa could produce beta lactamase enzyme to beta lactam antibiotics that causes many problems. The purpose of this study is analysis of the isolated of Pseudomonas from clinical specimens and this was done for the first time in Isfahan.Methods: A total of 98 isolates of P. aeruginosa from various clinical samples collected, then identified by biochemical tests. The antibiotic sensitivity of strains was performed by Kirby-Bauer method.Findings: The pattern of resistance to antibiotics showed that the greatest strength was in the burn specimen and 30 samples of the strains isolated from burns. In the 30 strains (%100) were resistances to more than three antibiotic (multi-drug resistant). Maximum resistance to Cefodoxime, amoxiclave, Cefexime, Cefotaxime and ceftizoxime respectively and the most sensitive to Ciprofloxsazine and gentamicin. In this study 63 strains showed the full resistance to ceftazidime and Cefotaxime s and ESBL test was done that revealed 23 strains of ESBL were negative and 40 strains did not inhibit by Clavulanic acid. All of the burn samples resistant to ceftazidime and did not inhibit by Clavulanic acid. Conclusion: In regarding to the high prevalence of P. aeruginosa with Multiple Drug Resistant, increased resistance to antibiotics and the high incidence of ESBL in the strains in clinical samples, it is essential, extended control measures to reduce this pathogens.

Keywords

References

  1. Doggett R. Microbiology of pseudomonas aeruginosa. In: Aduan RP, editor. Pseudomonas aeruginosa: clinical manifestations of infection and current therapy. New York: Academic Press; 1979. p. 120.
  2. Bergey DH, Buchanan RE, Gibbons NE, American Society for Microbiology. Bergey's manual of determinative bacteriology. 8th ed. Philadelphia: Williams & Wilkins Co; 1974 .p. 141-219.
  3. Campa M, Bendinelli M, Friedman H. Pseudomonas aeruginosa as an opportunistic pathogen. New York: Plenum Press; 1993 .p. 12-5.
  4. Topley WWC, Ajello L, Collier L, Wilson GS, Balows A, Hay RJ. Topley & Wilson's microbiology and microbial infections: Medical mycology. 9th ed. New York: Arnold; 1998.
  5. DeBell RM. Production of exotoxin A by Pseudomonas aeruginosa in a chemically defined medium. Infect Immun 1979; 24(1): 132-8. p. 245-1138.
  6. Murray PR, Rosenthal KS, Pfaller MA. Medical microbiology. 5th ed. Philadelphia: Elsevier Mosby; 2005.
  7. Estahbanati HK, Kashani PP, Ghanaatpisheh F. Frequency of Pseudomonas aeruginosa serotypes in burn wound infections and their resistance to antibiotics. Burns 2002; 28(4): 340-8.
  8. Shahcheraghi F, Feizabadi MM, Yamin V, Abiri R, Abedian Z. Serovar determination, drug resistance patterns and plasmid profiles of Pseudomonas aeruginosa isolated from burn patients at two hospitals of Tehran (IRAN). Burns 2003; 29(6): 547-51.
  9. Maleknezhad P, Aligholi M, Moosavi S. Study of pseudomonas aeroginosa resistance to penicillines, cephalosporins and aminoglycosides. Tehran Univ Med J 1998; 56(4): 23-8.
  10. Aduan RP. Pseudomonas aeruginosa: clinical manifestations of infection and current therapy. New York: Academic Press; 1979 .p. 3.
  11. Chanawong A, M'Zali FH, Heritage J, Lulitanond A, Hawkey PM. SHV-12, SHV-5, SHV-2a and VEB-1 extended-spectrum beta-lactamases in Gram-negative bacteria isolated in a university hospital in Thailand. J Antimicrob Chemother 2001; 48(6): 839-52.
  12. Rossolini GM, Mantengoli E. Treatment and control of severe infections caused by multiresistant Pseudomonas aeruginosa. Clin Microbiol Infect 2011; 11(Suppl 4): 17-32.
  13. Navon-Venezia S, Ben-Ami R, Carmeli Y. Update on Pseudomonas aeruginosa and Acinetobacter baumannii infections in the healthcare setting. Curr Opin Infect Dis 2005; 18(4): 306-13.
  14. Knothe H, Shah P, Krcmery V, Antal M, Mitsuhashi S. Transferable resistance to cefotaxime, cefoxitin, cefamandole and cefuroxime in clinical isolates of Klebsiella pneumoniae and Serratia marcescens. Infection 1983; 11(6): 315-7.
  15. Bush K, Jacoby GA, Medeiros AA. A functional classification scheme for beta-lactamases and its correlation with molecular structure. Antimicrob Agents Chemother 1995; 39(6): 1211-33.
  16. Thomson KS, Prevan AM, Sanders CC. Novel plasmid-mediated beta-lactamases in enterobacteriaceae: emerging problems for new beta-lactam antibiotics. Curr Clin Top Infect Dis 1996; 16: 151-63.
  17. Howard C, van DA, Kelly G, Schooneveldt J, Nimmo G, Giffard PM. Identification and minisequencing-based discrimination of SHV beta-lactamases in nosocomial infection-associated Klebsiella pneumoniae in Brisbane, Australia. Antimicrob Agents Chemother 2002; 46(3): 659-64.
  18. Soltan Dallal MM, Molla Aghamirzaei H, Fallah Mehrabadi J, Rastegar Lari A, Sabbaghi A, Eshraghian MR, et al. Molecular detection of TEM and AmpC (Dha, mox) broad spectrum ?-lactamase in clinical isolates of Escherichia coli. Tehran Univ Med J 2010; 68(6): 315-20.
  19. Japoni A, Farshad S, Alborzi A, Kalani M, Nasiri J. Susceptibility patterns and cross-resistance of antibiotics against Pseudomonas aeruginosa isolated from burn patients in the South of Iran. Iranian Journal of Infectious Diseases and Tropical Medicine 2006; 35(11): 13-8.
  20. Mansori S, Chitsaz M, Hajihoseini R, Mirzaei M, Ghaini MH. Determining the resistance of clinical isolates producing Ampc btalactamases broad spectrum based on phenotypic and genotypic characteristics. Daneshvar 2009; 16(80): 61-70.
  21. Weldhagen GF, Prinsloo A. Molecular detection of GES-2 extended spectrum Beta-lactamase producing Pseudomonas aeruginosa in Pretoria, South Africa. Int J Antimicrob Agents 2004; 24(1): 35-8.
  22. Jiang X, Zhang Z, Li M, Zhou D, Ruan F, Lu Y. Detection of extended-spectrum beta-lactamases in clinical isolates of Pseudomonas aeruginosa. Antimicrob Agents Chemother 2006; 50(9): 2990-5.
  23. Nikan M, Chitsaz M, Motvayei M. Prevalence of broad-spectrum beta-lactamase ampc gene in clinical isolates of klebsiella pneumoniae. IJMM 2008; 2(2): 1-8.
  24. Mirsalehian A, Feizabadi MM, Akbari Nakhjavani F, Jabal ameli F, Goli HR. Prevalence of extended spectrum beta lactamases among strains of Pseudomonas aeruginosa isolated from burn patients. Tehran Univ Med J 2008; 66(5): 333-7.
  25. Shahcheraghi F, Nikbin VS, Shooraj F. PCR detection of PER &VEB &SHV and TEM lactamases in multidrug resistant P. aeruginoasa isolated from wound infections in two hospitals of Tehran. IJMM 2008; 1(4): 21-7.
  26. Mohajeri P. Determine the sensitivity and antibiotic resistance of P. aeruginosa strains isolated from various clinical specimens in patients referred to medical centers in Kermanshah. Behbood 2003; 7(4): 11-20.
  27. (30) Afrasiabian Sh, Heidari M. Burn wound infection and antibiotic resistance patterns in patients hospitalized in a hospital burn unit Tohid. Iranian Journal of Infectious Diseases 2008; 13(42): 61-5.
  28. Chayakulkeeree M, Junsriwong P, Keerasuntonpong A, Tribuddharat C, Thamlikitkul V. Epidemiology of extended-spectrum beta-lactamase producing gram-negative bacilli at Siriraj Hospital, Thailand, 2003. Southeast Asian J Trop Med Public Health 2005; 36(6): 1503-9.
  29. Lee S, Park YJ, Kim M, Lee HK, Han K, Kang CS, et al. Prevalence of Ambler class A and D beta-lactamases among clinical isolates of Pseudomonas aeruginosa in Korea. J Antimicrob Chemother 2005; 56(1): 122-7.
  30. Celenza G, Pellegrini C, Caccamo M, Segatore B, Amicosante G, Perilli M. Spread of bla(CTX-M-type) and bla(PER-2) beta-lactamase genes in clinical isolates from Bolivian hospitals. J Antimicrob Chemother 2006; 57(5): 975-8.
  31. Hoseinzadegan H, Azadpour M, Mohammadi F. Screening of extended spectrum beta lactamase producing gram negative bacilli isolated from clinical cases. Medical Laboratory Journal 2007; 1(2.(
  32. Weldhagen GF, Poirel L, Nordmann P. Ambler class A extended-spectrum beta-lactamases in Pseudomonas aeruginosa: novel developments and clinical impact. Antimicrob Agents Chemother 2003; 47(8): 2385-92.
  33. Poirel L, Weldhagen GF, De CC, Nordmann P. A nosocomial outbreak of Pseudomonas aeruginosa isolates expressing the extended-spectrum beta-lactamase GES-2 in South Africa. J Antimicrob Chemother 2002; 49(3): 561-5.
  34. Shahcheraghi F, Nikbin VS, Shooraj F, Shafiei M. Investigation of blaIMP-1, blaVIM-1 and blaSPM-1 MBL genes among clinical strains of pseudomonas aeruginosa isolated from Imam Khomeini Hospital, Tehran, Iran. Shahid Beheshti University of Medical Sciences 2009; 14(2): 67-72.
Journal of Isfahan Medical School
Volume 29, Issue 154 - Serial Number 154
July and August 2011
Pages 1365-1374

Files

History

  • Receive Date: 09 November 2011
  • Revise Date: 01 November 2024
  • Accept Date: 06 April 2022

Share

How to cite

Statistics